tiprankstipranks
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
US Market
IONS
Ionis Pharmaceuticals
RESEARCH TOOLSreports

Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

1,481 Followers
See the Price Targets and Ratings of:

IONS Analyst Ratings

Strong Buy
14Ratings
Strong Buy
11 Buy
3 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Ionis
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IONS Stock 12 Month Forecast

Average Price Target

$97.19
▲(29.43% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $97.19 with a high forecast of $120.00 and a low forecast of $72.00. The average price target represents a 29.43% change from the last price of $75.09.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","121":"$121","49.75":"$49.8","73.5":"$73.5","97.25":"$97.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97.19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$97.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$72.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,49.75,73.5,97.25,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.96,84.88615384615385,87.81230769230768,90.73846153846154,93.66461538461539,96.59076923076923,99.51692307692308,102.44307692307692,105.36923076923077,108.29538461538462,111.22153846153846,114.14769230769231,117.07384615384615,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.96,83.13153846153845,84.30307692307692,85.47461538461538,86.64615384615384,87.8176923076923,88.98923076923077,90.16076923076923,91.3323076923077,92.50384615384615,93.67538461538462,94.84692307692308,96.01846153846154,{"y":97.19,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.96,81.19384615384615,80.4276923076923,79.66153846153846,78.89538461538461,78.12923076923076,77.36307692307692,76.59692307692308,75.83076923076923,75.06461538461538,74.29846153846154,73.5323076923077,72.76615384615384,{"y":72,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.03,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 69,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 51, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 47, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.11,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.07,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.96,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$120.00Average Price Target$97.19Lowest Price Target$72.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on IONS
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$120
Buy
59.81%
Upside
Reiterated
03/31/26
Ionis: Olezarsen’s Expanded Global Opportunity and Strengthened Royalty Streams Support Reiterated Buy and $120 Target
Jefferies Analyst forecast on IONS
Akash Tewari
Jefferies
Jefferies
$96→$113
Buy
50.49%
Upside
Reiterated
03/26/26
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (NASDAQ: BIOA) and Ionis Pharmaceuticals (NASDAQ: IONS)
Barclays Analyst forecast on IONS
Eliana Merle
Barclays
Barclays
$95→$106
Buy
41.16%
Upside
Assigned
03/26/26
Barclays Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)
William Blair Analyst forecast on IONS
Myles Minter
William Blair
William Blair
$72.7
Buy
-3.18%
Downside
Reiterated
03/25/26
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS) and Ionis Pharmaceuticals (NASDAQ: IONS)
TD Cowen Analyst forecast on IONS
Yaron Werber
TD Cowen
TD Cowen
$110
Buy
46.49%
Upside
Reiterated
03/25/26
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Terns Pharmaceuticals (TERN)
Bank of America Securities Analyst forecast on IONS
Jason Gerberry
Bank of America Securities
Bank of America Securities
$100
Buy
33.17%
Upside
Reiterated
03/25/26
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), KalVista Pharmaceuticals (NASDAQ: KALV) and Ionis Pharmaceuticals (NASDAQ: IONS)
Needham Analyst forecast on IONS
Joseph Stringer
Needham
Needham
$103→$105
Buy
39.83%
Upside
Assigned
03/25/26
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (NASDAQ: KALV) and Ionis Pharmaceuticals (NASDAQ: IONS)
Stifel Nicolaus Analyst forecast on IONS
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$77→$83
Hold
10.53%
Upside
Assigned
03/25/26
Ionis Pharmaceuticals price target raised to $83 from $77 at StifelIonis Pharmaceuticals price target raised to $83 from $77 at Stifel
Morgan Stanley Analyst forecast on IONS
Michael Ulz
Morgan Stanley
Morgan Stanley
$95
Buy
26.51%
Upside
Reiterated
03/23/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), GE Healthcare Technologies Inc (NASDAQ: GEHC) and Insmed (NASDAQ: INSM)
Piper Sandler Analyst forecast on IONS
Allison Bratzel
Piper Sandler
Piper Sandler
$87→$100
Buy
33.17%
Upside
Reiterated
02/27/26
Ionis Pharmaceuticals price target raised to $100 from $87 at Piper SandlerIonis Pharmaceuticals price target raised to $100 from $87 at Piper Sandler
Goldman Sachs Analyst forecast on IONS
Salveen Richter
Goldman Sachs
Goldman Sachs
$69→$72
Hold
-4.12%
Downside
Reiterated
02/25/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amarin (NASDAQ: AMRN), Ionis Pharmaceuticals (NASDAQ: IONS) and Repligen (NASDAQ: RGEN)
RBC Capital Analyst forecast on IONS
Luca Issi
RBC Capital
RBC Capital
$95
Buy
26.51%
Upside
Reiterated
02/25/26
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (NASDAQ: GUTS), Ionis Pharmaceuticals (NASDAQ: IONS) and Axsome Therapeutics (NASDAQ: AXSM)
Wells Fargo Analyst forecast on IONS
Yanan Zhu
Wells Fargo
Wells Fargo
$100
Buy
33.17%
Upside
Reiterated
01/14/26
Bernstein Analyst forecast on IONS
William Pickering
Bernstein
Bernstein
$65→$89
Hold
18.52%
Upside
Reiterated
01/13/26
Ionis Pharmaceuticals (IONS) Gets a Hold from Bernstein
Leerink Partners Analyst forecast on IONS
Mani Foroohar
Leerink Partners
Leerink Partners
$85→$100
Buy
33.17%
Upside
Reiterated
12/15/25
Leerink Partners Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on IONS
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$120
Buy
59.81%
Upside
Reiterated
03/31/26
Ionis: Olezarsen’s Expanded Global Opportunity and Strengthened Royalty Streams Support Reiterated Buy and $120 Target
Jefferies Analyst forecast on IONS
Akash Tewari
Jefferies
Jefferies
$96→$113
Buy
50.49%
Upside
Reiterated
03/26/26
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (NASDAQ: BIOA) and Ionis Pharmaceuticals (NASDAQ: IONS)
Barclays Analyst forecast on IONS
Eliana Merle
Barclays
Barclays
$95→$106
Buy
41.16%
Upside
Assigned
03/26/26
Barclays Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)
William Blair Analyst forecast on IONS
Myles Minter
William Blair
William Blair
$72.7
Buy
-3.18%
Downside
Reiterated
03/25/26
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS) and Ionis Pharmaceuticals (NASDAQ: IONS)
TD Cowen Analyst forecast on IONS
Yaron Werber
TD Cowen
TD Cowen
$110
Buy
46.49%
Upside
Reiterated
03/25/26
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Terns Pharmaceuticals (TERN)
Bank of America Securities Analyst forecast on IONS
Jason Gerberry
Bank of America Securities
Bank of America Securities
$100
Buy
33.17%
Upside
Reiterated
03/25/26
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), KalVista Pharmaceuticals (NASDAQ: KALV) and Ionis Pharmaceuticals (NASDAQ: IONS)
Needham Analyst forecast on IONS
Joseph Stringer
Needham
Needham
$103→$105
Buy
39.83%
Upside
Assigned
03/25/26
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (NASDAQ: KALV) and Ionis Pharmaceuticals (NASDAQ: IONS)
Stifel Nicolaus Analyst forecast on IONS
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$77→$83
Hold
10.53%
Upside
Assigned
03/25/26
Ionis Pharmaceuticals price target raised to $83 from $77 at StifelIonis Pharmaceuticals price target raised to $83 from $77 at Stifel
Morgan Stanley Analyst forecast on IONS
Michael Ulz
Morgan Stanley
Morgan Stanley
$95
Buy
26.51%
Upside
Reiterated
03/23/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), GE Healthcare Technologies Inc (NASDAQ: GEHC) and Insmed (NASDAQ: INSM)
Piper Sandler Analyst forecast on IONS
Allison Bratzel
Piper Sandler
Piper Sandler
$87→$100
Buy
33.17%
Upside
Reiterated
02/27/26
Ionis Pharmaceuticals price target raised to $100 from $87 at Piper SandlerIonis Pharmaceuticals price target raised to $100 from $87 at Piper Sandler
Goldman Sachs Analyst forecast on IONS
Salveen Richter
Goldman Sachs
Goldman Sachs
$69→$72
Hold
-4.12%
Downside
Reiterated
02/25/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amarin (NASDAQ: AMRN), Ionis Pharmaceuticals (NASDAQ: IONS) and Repligen (NASDAQ: RGEN)
RBC Capital Analyst forecast on IONS
Luca Issi
RBC Capital
RBC Capital
$95
Buy
26.51%
Upside
Reiterated
02/25/26
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (NASDAQ: GUTS), Ionis Pharmaceuticals (NASDAQ: IONS) and Axsome Therapeutics (NASDAQ: AXSM)
Wells Fargo Analyst forecast on IONS
Yanan Zhu
Wells Fargo
Wells Fargo
$100
Buy
33.17%
Upside
Reiterated
01/14/26
Bernstein Analyst forecast on IONS
William Pickering
Bernstein
Bernstein
$65→$89
Hold
18.52%
Upside
Reiterated
01/13/26
Ionis Pharmaceuticals (IONS) Gets a Hold from Bernstein
Leerink Partners Analyst forecast on IONS
Mani Foroohar
Leerink Partners
Leerink Partners
$85→$100
Buy
33.17%
Upside
Reiterated
12/15/25
Leerink Partners Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ionis Pharmaceuticals

3 Months
xxx
Success Rate
21/34 ratings generated profit
62%
Average Return
+6.85%
reiterated a xxx
 rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 61.76% of your transactions generating a profit, with an average return of +6.85% per trade.
1 Year
Gary NachmanRaymond James
Success Rate
18/22 ratings generated profit
82%
Average Return
+35.42%
reiterated a buy rating 6 months ago
Copying Gary Nachman's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +35.42% per trade.
2 Years
xxx
Success Rate
33/34 ratings generated profit
97%
Average Return
+41.57%
reiterated a xxx
 rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 97.06% of your transactions generating a profit, with an average return of +41.57% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IONS Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
5
1
1
0
4
Buy
51
34
23
27
26
Hold
47
33
19
18
20
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
104
68
43
45
50
In the current month, IONS has received 30 Buy Ratings, 20 Hold Ratings, and 0 Sell Ratings. IONS average Analyst price target in the past 3 months is 97.19.
Each month's total comprises the sum of three months' worth of ratings.

IONS Financial Forecast

IONS Earnings Forecast

Next quarter’s earnings estimate for IONS is -$0.85 with a range of -$1.21 to -$0.39. The previous quarter’s EPS was -$1.41. IONS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.
Next quarter’s earnings estimate for IONS is -$0.85 with a range of -$1.21 to -$0.39. The previous quarter’s EPS was -$1.41. IONS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.

IONS Sales Forecast

Next quarter’s sales forecast for IONS is $197.45M with a range of $159.14M to $235.00M. The previous quarter’s sales results were $203.00M. IONS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.
Next quarter’s sales forecast for IONS is $197.45M with a range of $159.14M to $235.00M. The previous quarter’s sales results were $203.00M. IONS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.

IONS Stock Forecast FAQ

What is IONS’s average 12-month price target, according to analysts?
Based on analyst ratings, Ionis Pharmaceuticals’s 12-month average price target is 97.19.
    What is IONS’s upside potential, based on the analysts’ average price target?
    Ionis Pharmaceuticals has 29.43% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IONS a Buy, Sell or Hold?
          Ionis Pharmaceuticals has a consensus rating of Strong Buy which is based on 11 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Ionis Pharmaceuticals’s price target?
            The average price target for Ionis Pharmaceuticals is 97.19. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $120.00 ,the lowest forecast is $72.00. The average price target represents 29.43% Increase from the current price of $75.09.
              What do analysts say about Ionis Pharmaceuticals?
              Ionis Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of IONS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.